Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Maxim Pharmaceuticals (NasdaqNM:MAXM)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | Msgs | Insider | Options
Location
8899 University Center Lane, Suite 400
San Diego, CA 92122
Phone: (858) 453-4040
Fax: (858) 453-5005
Employees (last reported count): 144
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 23%
·Over the last 6 months:
 · 2 insider buys; 2,000  shares
·Institutional: 14% (18% of float)
(83 institutions)
·Net Inst. Buying: 214.0K shares (+6.29%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Maxim Pharmaceuticals Inc. is a late-stage biopharmaceutical company developing advanced drugs and therapies for cancer, infectious diseases, degenerative diseases and topical disorders. The Company's lead drug candidate Ceplene (histamine dihydrochloride, formerly known as Maxamine), is designed to improve immunotherapy by protecting critical immune cells, and is administered in combination with cytokines. The Company is also developing MaxDerm, a Ceplene-related series of drug candidates for the treatment of certain topical disorders. Furthermore, through its proprietary high-throughput screening technology, the Company has identified compounds that may serve as inhibitors and activators of caspases, key enzymes that modulate and carry out the cellular signaling pathways involved in programmed cell death, also known as apoptosis.
More from Market Guide: Expanded Business Description

Financial Summary
MAXM develops novel therapeutics for the treatment of cancer and infectious diseases. Its lead drug, Ceplene, is designed to facilitate an immune system mechanism to achieve full anti-tumor and anti-infection potential. For the six months ended 3/01, revenues totalled $1.7 million, up from $288 thousand. Net loss applicable to Com. decreased 9% to $22.7 million. Revenues reflect the licensing of anti-cancer compounds. Lower loss benefitted from the absence of preferred dividend.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 827; after tax earnings were -6,429. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Larry Stambaugh, 53
Chairman of Directors, Pres and CEO
$515K--  
Dale Sander, 41
CFO, VP-Fin., Sec.
264K$956K
Kurt Gehlsen, Ph.D., 44
VP of Devel. and CTO
310K1.4M
Geoffrey Altman, 39
VP of Marketing and Sales
190K--  
Dollar amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:MAXMAs of 31-Aug-2001
Price and Volume
52-Week Low
on 27-Dec-2000
$4.813
Recent Price$5.70 
52-Week High
on 14-Sep-2000
$68.00 
Beta0.61 
Daily Volume (3-month avg)95.0K
Daily Volume (10-day avg)48.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-90.6%
52-Week Change
relative to S&P500
-87.4%
Share-Related Items
Market Capitalization$132.4M
Shares Outstanding23.2M
Float17.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$8.38 
Earnings (ttm)-$1.66 
Earnings (mrq)-$0.28 
Sales (ttm)$0.15 
Cash (mrq*)$6.98 
Valuation Ratios
Price/Book (mrq*)0.68 
Price/EarningsN/A 
Price/Sales (ttm)37.72 
Income Statements
Sales (ttm)$3.48M
EBITDA (ttm*)-$92.6M
Income available to common (ttm)-$38.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsSep 30
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-17.00%
Return on Equity (ttm)-18.22%
Financial Strength
Current Ratio (mrq*)14.93 
Debt/Equity (mrq*)0.01 
Total Cash (mrq)$155.1M
Short Interest
As of 8-Aug-2001
Shares Short1.60M
Percent of Float8.9%
Shares Short
(Prior Month)
1.65M
Short Ratio31.33 
Daily Volume51.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.